MOTS-c Alleviates Diabetic Heart Damage by Calming Inflammation Pathway
MOTS-c regulates the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy.
Background
Chronic low-grade inflammation is a hallmark of diabetes, frequently leading to severe cardiovascular events and myocardial damage, collectively known as diabetic cardiomyopathy. This condition significantly increases the risk of debilitating cardiac complications. While the mitochondria-derived peptide MOTS-c shows promise in regulating glucose and lipid metabolism, its precise impact on cardiac structure and inflammation in the context of diabetic cardiomyopathy, specifically via the ROS/TXNIP/NLRP3 pathway, remained unclear.